- ISIN
- US29772L1089
- CUSIP
- 29772L108
- Sector
- Healthcare
- IPO Date
- Nov 13, 2018
Highlights
- Market Cap
- $1.27B
- Enterprise Value
- $1.28B
- EPS (TTM)
- -$0.05
- Total Revenue (TTM)
- $86.93M
- Gross Profit (TTM)
- $47.61M
- EBITDA (TTM)
- $5.70M
- Year Range
- $13.99 - $50.18
- Target Price
- $25.00
- ROA (TTM)
- -1.51%
- ROE (TTM)
- -4.82%
- Avg. Volume (1M)
- 540K
- Avg. Volume Value (1M)
- $22.65M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ETON Performance Chart
Eton Pharmaceuticals Inc (ETON) is up 174.5% since the beginning of the year. At $46 per share, ETON is trading 7.5% below its 52-week high of $50. Investors who bought $1,000 worth of ETON shares 5 years ago would now be looking at an investment worth $9,031.
Loading charts...
Compare this symbol against anything
Returns By Period
Eton Pharmaceuticals Inc (ETON) has returned 174.51% so far this year and 228.52% over the past 12 months.
Eton Pharmaceuticals Inc
- 1D
- -5.32%
- 1M
- 23.79%
- 6M
- 209.26%
- YTD
- 174.51%
- 1Y
- 228.52%
- 3Y*
- 154.38%
- 5Y*
- 55.29%
- 10Y*
- —
- ALL TIME*
- 29.32%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ETON Monthly Returns History
Based on dividend-adjusted daily data since Nov 13, 2018, ETON's average daily return is +0.18%, while the average monthly return is +3.69%. At this rate, an investment would double in approximately 1.6 years.
Historically, 52% of months were positive and 48% were negative. The best month was Nov 2024 with a return of +59.7%, while the worst month was Nov 2021 at -32.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.
On a daily basis, ETON closed higher 50% of trading days. The best single day was Aug 11, 2023 with a return of +38.1%, while the worst single day was Mar 16, 2020 at -20.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.24% | 13.19% | 45.26% | -2.27% | 26.24% | 18.88% | 28.23% | 174.51% | |||||
| 2025 | 32.73% | -11.20% | -17.32% | 29.82% | 12.11% | -24.56% | -0.63% | 22.25% | 25.53% | -17.12% | -10.33% | 4.71% | 26.95% |
| 2024 | 6.62% | -4.71% | -15.73% | -6.67% | 1.43% | -7.32% | 9.42% | 27.78% | 30.43% | 41.17% | 59.74% | -1.55% | 204.11% |
| 2023 | 23.40% | 7.18% | 3.22% | -5.71% | 9.09% | -11.87% | -19.20% | 59.57% | -7.33% | 1.20% | -16.11% | 23.73% | 55.32% |
| 2022 | -13.75% | 1.62% | 15.96% | -19.04% | -13.88% | -13.82% | 2.29% | -15.67% | -7.08% | 21.43% | 18.43% | -6.62% | -34.27% |
| 2021 | 9.72% | -11.32% | -7.46% | 18.58% | -18.66% | -12.75% | -16.56% | 2.53% | -4.36% | 14.29% | -32.29% | 10.00% | -47.23% |
Benchmark Metrics
Eton Pharmaceuticals Inc has an annualized alpha of 40.01%, beta of 0.81, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since November 13, 2018.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (88.22%) than losses (14.42%) - typical of diversified or defensive assets.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 40.01%
- Beta
- 0.81
- R²
- 0.06
- Upside Capture
- 88.22%
- Downside Capture
- 14.42%
Return for Risk
Risk / Return Rank
ETON ranks 97 for risk / return — above 97% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Eton Pharmaceuticals Inc (ETON) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ETON | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.70 | ||
| Sortino ratioReturn per unit of downside risk | +2.22 | ||
| Omega ratioGain probability vs. loss probability | 1.55 | 1.25 | +0.30 |
| Calmar ratioReturn relative to maximum drawdown | 6.34 | 2.00 | +4.34 |
| Martin ratioReturn relative to average drawdown | 13.13 | 8.49 | +4.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eton Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eton Pharmaceuticals Inc was 79.94%, occurring on Oct 20, 2022. Recovery took 519 trading sessions.
The current Eton Pharmaceuticals Inc drawdown is 5.32%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-79.94%Oct 2022 | 1y 8mo | 2y 25d | 3y 8moFeb 2021 - Nov 2024 | Bear market2022 |
-67.13%Mar 2020 | 8mo 11d | 6mo 4d | 1y 2moJul 2019 - Sep 2020 | COVID crash2020 |
-37.15%Apr 2025 | 2mo 1d | 1mo 7d | 3mo 8dFeb 2025 - May 2025 | 2025 selloff2025 |
-36.17%Feb 2026 | 4mo 8d | 1mo 16d | 5mo 24dSep 2025 - Mar 2026 | — |
-33.33%Jun 2025 | 1mo 3d | 3mo 3d | 4mo 6dMay 2025 - Sep 2025 | 2025 selloff2025 |
Drawdown Indicators
| ETON | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.94% | -56.78% | -23.16% |
Max Drawdown (1Y)Largest decline over 1 year | -36.17% | -9.10% | -27.07% |
Max Drawdown (3Y)Largest decline over 3 years | -45.65% | -18.90% | -26.75% |
Max Drawdown (5Y)Largest decline over 5 years | -69.35% | -25.43% | -43.92% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -5.32% | -1.58% | -3.74% |
Average DrawdownAverage peak-to-trough decline | -36.98% | -10.70% | -26.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.44% | 2.14% | +15.30% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eton Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Eton Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ETON relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ETON has a P/S ratio of 15.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ETON in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ETON has a P/B value of 47.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ETON
Add Eton Pharmaceuticals Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ETON